Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human Complement Factor H Anticorps:
anti-Mouse (Murine) Complement Factor H Anticorps:
anti-Rat (Rattus) Complement Factor H Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal Complement Factor H Primary Antibody pour IP, ELISA - ABIN2473069
Fontaine, Demares, Koistinen, Day, Davrinche, Sim, Ripoche: Truncated forms of human complement factor H. dans The Biochemical journal 1989
Show all 4 Pubmed References
Human Polyclonal Complement Factor H Primary Antibody pour ELISA, WB - ABIN250548
Klein, Zeiss, Chew, Tsai, Sackler, Haynes, Henning, SanGiovanni, Mane, Mayne, Bracken, Ferris, Ott, Barnstable, Hoh: Complement factor H polymorphism in age-related macular degeneration. dans Science (New York, N.Y.) 2005
Human Polyclonal Complement Factor H Primary Antibody pour ID, WB - ABIN253380
Radu, Hu, Yuan, Welch, Makshanoff, Lloyd, McMullen, Travis, Bok: Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. dans The Journal of biological chemistry 2011
Human Monoclonal Complement Factor H Primary Antibody pour IHC (fro), FACS - ABIN2473067
Harrison, Lachmann: The physiological breakdown of the third component of human complement. dans Molecular immunology 1980
Show all 2 Pubmed References
inhibition of the alternative pathway by factor H, with a concentration equivalent to a high physiological level, strongly reduced C5a levels and decreased proinflammatory cytokine production in human peripheral blood mononuclear cells.
Complement factor H Y402H (rs1061170) and age-related maculopathy susceptibility2 (ARMS2 (Montrer ARMS2 Anticorps))/LOC387715 A69S (rs10490924) polymorphisms shown to have significant association with age-related macular degeneration (Meta-Analysis).
Regression analysis showed that ARMS2 (Montrer ARMS2 Anticorps) TT genotype has a statistically significant effect on retinal angiomatous proliferation versus age-related macular degeneration compared to CFH genotypes (P < 0.001).
This study enclosed strong synergistic association of risk genotypes of C3 and CFH Y402H with AMD (Montrer AMD1 Anticorps). We also revealed synergistic influence of CCL2 (Montrer CCL2 Anticorps)-2518 and the at-risk genotype of the C3 in AMD (Montrer AMD1 Anticorps) with an estimated AP = 50.9% (adjusted AP = 24.7%). Present findings show that CCL2 (Montrer CCL2 Anticorps)-2518 polymorphism is not an innocent bystander (Montrer SEPT1 Anticorps) in AMD (Montrer AMD1 Anticorps) susceptibility when combined with the at-risk genotype of C3 (R102G).
Our results suggest that factor H can interfere with mycobacterial entry into macrophages and modulate inflammatory cytokine responses, particularly during the initial stages of infection, thus affecting the extracellular survival of the pathogen.
To our knowledge, this is the first evaluation of the involvement of the CFHR3 (Montrer CFHR3 Anticorps)/CFHR1 (Montrer CFHR1 Anticorps) deletion and age-related macular degeneration in CFH Y402H polymorphism Brazilian patients.
The findings of the present study provide evidence that CFH gene variants and ARMS2 (Montrer ARMS2 Anticorps)/HTRA1 (Montrer HTRA1 Anticorps) genes play a major role in the genetic susceptibility to AMD (Montrer AMD1 Anticorps) in a Greek population. These findings are of direct relevance for disease and help mapping the genetic chart of AMD (Montrer AMD1 Anticorps).
Our results suggest the contribution of all four predicted CFH polymorphisms in age-related macular degeneration (AMD (Montrer AMD1 Anticorps)) susceptibility among the Iranian population. This association with CFH may lead to early detection and new strategies for prevention and treatment of AMD (Montrer AMD1 Anticorps).
Development of polypoidal choroidal vasculopathy (PCV) in the unaffected fellow eye is associated with ARMS2 (Montrer ARMS2 Anticorps) A69S genotype in patients with unilateral PCV.
Identification of rare CFH variant carriers may be important for upcoming complement-inhibiting therapies. Patients with an extensive drusen area, drusen with crystalline appearance, and drusen nasal to the optic disc are more likely to have a rare variant in the CFH gene.
this study shows that complement regulatory protein (Montrer TGFB1 Anticorps) Factor H is a soluble prion (Montrer PRNP Anticorps) receptor that potentiates peripheral prion (Montrer PRNP Anticorps) pathogenesis
Factor H and Crry (Montrer CR1L Anticorps) are critical for regulating complement activation at distinct anatomic sites within the kidney.
VEGF (Montrer VEGFA Anticorps) inhibition decreases local CFH and other complement regulators in the eye and kidney through reduced VEGFR2 (Montrer KDR Anticorps)/PKC-alpha (Montrer PKCa Anticorps)/CREB (Montrer CREB1 Anticorps) signaling.
environmental factors can drive retinal disease in these mice when linked to complement deficits impairing immune function. Both groups of mice had similar levels of retinal amyloid beta accumulation. Consequently there is no direct link between this and inflammation in Cfh(-/-) mice.
absence of plasma CfH conferred susceptibility to glomerulonephritis
This new understanding of the complicated interactions of CFH in AMD (Montrer AMD1 Anticorps)-like pathology provides an improved foundation for the development of targeted therapies for AMD (Montrer AMD1 Anticorps)
data suggest that altered interactions of Cfh with MDA-modified proteins may be relevant in explaining the effects of the Cfh variant.
Cfh and Cfhr2 (Montrer CFHR2 Anticorps) genes are expressed in the mouse outer retina. Only Cfh mRNA was detected in the retinal pigment epithelium, but no protein.
A spectrum of complement dysregulation was modeled on the APOE4 age related macular degeneration mouse model by crossing these mice to complement factor H knockout (cfh-/-) mice to test the impact of excess complement activation.
Data indicate that co-deficiency of factor H (FH) and MASP-1/MASP-3 (Montrer MASP1 Anticorps) did not ameliorate either the plasma Complement C3 (Montrer C3 Anticorps) (C3) activation or glomerular C3 accumulation in FH-deficient mice.
interaction between sialylated Neisseria gonorrhoeae and factor H [factor H]
Results report the molecular cloning and identification of complement factor H and complement factor H-like 1-4 (CFHL1 (Montrer CFHR1 Anticorps)-4) in Danio rerio.
This gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation, restricting this innate defense mechanism to microbial infections. Mutations in this gene have been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
H factor 1 (complement)
, H factor 2 (complement)
, adrenomedullin binding protein
, age-related maculopathy susceptibility 1
, factor H
, factor H-like 1
, complement regulator factor H
, complement factor H
, complement factor H related protein 3A4/5G4
, protein beta-1-H
, complement component factor H
, complement inhibitory factor H
, platelet complement factor H
, complement factor H L homeolog